Status:
COMPLETED
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Vical
Conditions:
Cytomegalovirus Infection
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
Objectives of this trial are to: Evaluate the kinetics and magnitude of the CMV-specific immune response post-Towne challenge (3000 pfu) in healthy CMV-seronegative volunteers who receive VCL CT02 ad...
Detailed Description
This is a Phase 1, single-center, randomized, open-label trial of the live, attenuated Towne CMV vaccine administered as a "challenge" to healthy, CMV-seronegative, adult subjects who previously recei...
Eligibility Criteria
Inclusion
- 18 to 45 years of age
- Normal lab values at study entry
- Good general health
- Negative CMV IgG antibody test
Exclusion
- CMV seropositive
- Recent vaccination(s)
- Immunodeficiency
- Vaccination with investigational CMV vaccine(s)
- Pregnant or breast-feeding
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00373412
Start Date
October 1 2006
Last Update
May 8 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Positive Health Program, 995 Potrero, 4th Floor
San Francisco, California, United States, 94110